Related Experiment Videos
Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients
Abstract:
Twenty-nine patients with primary or secondary hypoplastic bone-marrow were treated successfully with ceftazidime alone for established septicaemia caused by Pseudomonas aeruginosa of which 38% strains were gentamicin-resistant . All the patients were neutropenic at the start of therapy; most were cured with microbiological confirmation before the bone marrow had regenerated. One patient died of cerebral haemorrhage due to profound thrombocytopenia without evidence of infection at autopsy. Significant toxicity was not observed. Ceftazidime alone is, therefore, a safe and effective treatment for infections caused by this organism even in the neutropenic patient.
Insights
Ceftazidime effectively treated Pseudomonas aeruginosa septicemia in neutropenic patients with hypoplastic bone marrow. This antibiotic demonstrated safety and efficacy, even against gentamicin-resistant strains, offering a viable treatment option.
Area of Science:
- Infectious Diseases
- Hematology
- Pharmacology
Background:
- Hypoplastic bone marrow predisposes patients to severe infections, particularly Pseudomonas aeruginosa septicemia.
- Neutropenia significantly increases the risk of mortality from bacterial infections.
- Pseudomonas aeruginosa is a common opportunistic pathogen, often exhibiting antibiotic resistance.
Purpose of the Study:
- To evaluate the efficacy and safety of ceftazidime monotherapy in neutropenic patients with hypoplastic bone marrow and Pseudomonas aeruginosa septicemia.
- To assess treatment outcomes in patients with gentamicin-resistant Pseudomonas aeruginosa strains.
Main Methods:
- A cohort of 29 patients with hypoplastic bone marrow received ceftazidime monotherapy for established Pseudomonas aeruginosa septicemia.
- Patients were neutropenic at the initiation of treatment.
- Clinical and microbiological outcomes, as well as toxicity, were monitored.
Main Results:
- Ceftazidime treatment was successful in the majority of patients, with microbiological cure achieved before bone marrow regeneration.
- 38% of Pseudomonas aeruginosa strains were resistant to gentamicin, highlighting the need for alternative antibiotics.
- No significant toxicity was observed during ceftazidime therapy.
Conclusions:
- Ceftazidime monotherapy is a safe and effective treatment for Pseudomonas aeruginosa septicemia in neutropenic patients with hypoplastic bone marrow.
- Ceftazidime provides a crucial therapeutic option, especially when faced with gentamicin-resistant Pseudomonas aeruginosa strains.